Leerink Partners analyst Paul Matteis raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $123.00 (from $85.00) while maintaining an Outperform rating.

Analyst PT Change

Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to BuyNovember 10, 2017 8:16 AM Sage Therapeutics (SAGE) PT Raised to $140 at Canaccord GenuityNovember 10, 2017 7:22 AM Sage Therapeutics (SAGE) PT Raised to $135 at CowenNovember 9, 2017 3:20 PM Sage Therapeutics (SAGE) PT Raised to $105 at StifelNovember 9, 2017 12:43 PM Sage Therapeutics (SAGE) PT Raised to $100 at Needham & CompanyNovember 9, 2017 11:34 AM Sage Therapeutics (SAGE) PT Raised to $145 at RBC CapitalNovember 9, 2017 10:47 AM Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMONovember 9, 2017 10:12 AM SAGE Therapeutics (SAGE): Primary Endpoints in Both Phase III PPD Trials Met - SuntrustNovember 9, 2017 7:17 AM SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary EndpointNovember 9, 2017 6:42 AM SAGE Therapeutics (SAGE) Says Brexanolone Achieved Primary Endpoints in Both Phase 3 Trials in Postpartum DepressionNovember 9, 2017 6:28 AM Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum DepressionNovember 9, 2017 6:00 AM